Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

Table 2

Comparison of clinical data after 12-month treatment of intravitreal aflibercept or bevacizumab for macular edema secondary to branch retinal occlusion.

	Aflibercept ()	Bevacizumab ()	value
Final BCVA (logMAR)			0.28
Changes in BCVA (logMAR)			0.39
Changes in BCVA (ETDRS letters)			0.35
Final BCVA ≥ 20/40	36/50 (72%)	36/54 (66.6%)	0.44
BCVA gains ≥ 3 lines	30/50 (60%)	28/54 (52.8%)	0.12
BCVA loss ≥ 1 line	2/50 (4%)	4/54 (7.4%)	0.15
Final CFT (μm)			0.26
Changes in CFT (μm)			0.17
Injection number			0.11

BCVA: best-corrected visual acuity.
CFT: central foveal thickness.